Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @

Zemplar -Drug Insights, 2016 – A DelveInsight Report

DelveInsight, the leading market research and consulting company has added new report Zemplar -Drug Insights, 2016 to its portfolio. With this launch DelveInsight now has 400+ Reports on Drug Insight. In addition to this our research expertise provides our clients with up to date information of market till date order has been placed.

The Drug Insight Reports provides client with details on global Zemplar -Drug Insights, 2016. It comprehensively includes:

  • Marketed details and the Global API Manufacturers details across the globe along with the location
  • Total sales estimation along with sales forecast till 2018
  • Detailed clinical assessment, patent information
  • SWOT analysis

The report on Zemplar -Drug Insights, 2016 will help in evaluating market scenario and harness opportunities for development by identifying the key patent expiry details and exclusivity with respect to Zemplar. In addition to this the detail sales forecast and SWOT analysis will help companies in finding collaborations and licensing partners.

DelveInsight is offering the Report at a price of USD 1000 as a single user license, USD 2000 as a site license and USD 3000 as a Global/Enterprise License.

For more information on API insight Reports, email at

Contact Us:

DelveInsight Business Research

New Delhi-110075, India

+91-11-45689769, +91-9650213330

 About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.